Antibiotic Use in Children: Prescribing trends
This bulletin aims to highlight variation in total antimicrobial prescribing volume in children, defined here as 0-14 years. It specifically focuses on the proportion of unique patients prescribed regular antimicrobials throughout 12 months. National antimicrobial guidance, good practice guidance and resources are identified to help support good prescribing in practice.
There are three versions of this publication; please select the appropriate version for your region below.
Prescribing Update Newsletter – Mar 2020
Prescribing support newsletters aim to inform readers of work done by the unit and work in progress, to help tailor local work plans and highlight any ‘topical’ issues in prescribing or medicines management.
If you have any suggestions for future topics for the newsletter, then please contact nuth.nyrdtc.rxsupp@nhs.net
Oral Vitamin B supplementation
This document aims to support the Regional Medicines Optimisation Committees (RMOC) position statement; “Oral vitamin B supplementation in alcoholism” by identifying CCGs and geographical areas where prescribing within primary care may not be in line with the recommendations.
There is ongoing prescribing of vitamin B complex products despite national and local recommendations that this should be reserved for supplementation in the context of refeeding syndrome. Medicines optimisation teams should be advised to review the formulary status of vitamin B compound products and implement a deprescribing programme if necessary.
This review is older than 18 months; in view of the continued emergence of new evidence, readers are recommended to re-check the biomedical literature.
There are three versions of this publication; please select the appropriate version for your region below.
Comparison of SGLT2 inhibitors (update)
Comparison tables are produced for prescribers and medicines management teams. They are designed to assist in prescribing and decision-making within a specific therapeutic area.
Several sodium-glucose co-transporter 2 inhibitors are marketed. This comparison table allows prescribers and other healthcare professionals to easily compare the characteristics of these medicines.
Levodopa inhalation powder for episodic motor fluctuations in Parkinson’s disease
Overview
New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs.
Inbrija®▼ (Acorda Therapeutics), a levodopa powder for oral inhalation, is licensed for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor.
This review is older than 18 months; in view of the continued emergence of new evidence, readers are recommended to re-check the biomedical literature.
Download the full review below to read more.
NICE has accredited the process used by the Regional Drug and Therapeutics Centre to produce New Drug Evaluations. Accreditation is valid until the 31st of December 2023.
For more information visit www.nice.org/accreditation
Antibiotic use in children: liquid vs. solid oral dosage forms
This bulletin addresses cost-effective prescribing of oral antimicrobials in children without dysphagia. Liquid antimicrobial preparations are significantly more expensive than solid oral dosage forms, so the bulletin aims to
present the current prescribing patterns of antimicrobial formulations in the paediatric population on a CCG Level.
This review is older than 18 months; in view of the continued emergence of new evidence, readers are recommended to re-check the biomedical literature.
There are three versions of this publication; please select the appropriate version for your region below.
Prescribing Update Newsletter – Jan 2020
Prescribing support newsletters aim to inform readers of work done by the unit and work in progress, to help tailor local work plans and highlight any ‘topical’ issues in prescribing or medicines management.
If you have any suggestions for future topics for the newsletter, then please contact nuth.nyrdtc.rxsupp@nhs.net
Long-Term Use Of PPIs – Bulletin
Long-term use of PPIs is not recommended in several indications as it has been linked to adverse effects including hypomagnesaemia, vitamin B12 deficiency, increased fracture risk and increased risk of MI.
This bulletin aims to highlight the current national guidance, potential adverse effects associated with long term PPI use and prescribing patterns on a CCG Level.
This review is older than 18 months; in view of the continued emergence of new evidence, readers are recommended to re-check the biomedical literature.
There are three versions of this publication; please select the appropriate version for your region below.
Prescribing Update Newsletter – Nov 2019
Prescribing support newsletters aim to inform readers of work done by the unit and work in progress, to help tailor local work plans and highlight any ‘topical’ issues in prescribing or medicines management.
If you have any suggestions for future topics for the newsletter, then please contact nuth.nyrdtc.rxsupp@nhs.net
Comparison of oscillating positive expiratory pressure devices
Comparison documents are designed to support prescribers and medicines management teams to maximise health gains through the optimum use of medicines within a specific therapeutic area.
Oscillating positive expiratory pressure (OPEP) devices are intended to promote clearance of excess mucus secretions in people with respiratory conditions such as chronic obstructive pulmonary disease, cystic fibrosis, and bronchiectasis. This comparison table allows prescribers and other healthcare professionals to easily compare the characteristics of these devices.
This review is older than 18 months; in view of the continued emergence of new evidence, readers are recommended to re-check the biomedical literature.